| |
| |
|
| Insider
Information: |
Gillis Steven |
| Relationship: |
10% Owner |
| City: |
Seattle |
| State: |
WA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
10 |
|
| Direct
Shares |
111,799 |
|
|
Indirect Shares
|
68,663,401 |
|
|
| Direct
Value |
$66,571 |
|
|
|
Indirect Value
|
$249,467,230 |
|
|
| Total
Shares |
68,775,200 |
|
|
| Total
Value |
$249,533,802 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
2
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-2.0
|
0.0
|
| Percentage
Gain/Loss : |
 -16.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Trubion Pharmaceuticals, Inc |
TRBN |
Ex. Chair. & President... |
2006-10-18 |
0 |
2010-10-28 |
0 |
Premium* |
|
|
Bluebird Bio, Inc. |
BLUE |
Director |
2015-07-28 |
18,633 |
2015-07-28 |
90,675 |
Premium* |
|
|
VBI Vaccines Inc |
VBIV |
Director |
2019-09-19 |
84,416 |
2019-09-19 |
13,026,057 |
Premium* |
|
|
Q32 Bio Inc |
QTTB |
Director |
2018-04-02 |
0 |
2018-04-02 |
6,068,695 |
Premium* |
|
|
Sienna Biopharmaceuticals, Inc. |
SNNA |
10% Owner |
2019-02-22 |
0 |
2019-02-22 |
1,865,800 |
Premium* |
|
|
Codiak Biosciences, Inc. |
CDAK |
Director |
2023-02-16 |
8,750 |
2022-09-13 |
7,503,903 |
Premium* |
|
|
Sana Biotechnology, Inc. |
SANA |
10% Owner |
|
0 |
2024-02-08 |
22,747,272 |
Premium* |
|
|
Verve Therapeutics, Inc. |
VERV |
10% Owner |
2021-06-21 |
0 |
2021-06-21 |
1,254,405 |
Premium* |
|
|
Da32 Life Science Tech Acquisiti... |
DALS |
10% Owner |
2023-07-28 |
0 |
2023-07-28 |
650,000 |
Premium* |
|
|
Prime Medicine, Inc. |
PRME |
10% Owner |
2022-10-24 |
0 |
2024-02-15 |
15,456,594 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PRME |
Prime Medicine, Inc. |
10% Owner |
– – • |
2024-02-15 |
4 |
B |
$6.25 |
$20,000,000 |
I/I |
3,200,000 |
3,200,000 |
1.5 |
% |
|
| SANA |
Sana Biotechnology, Inc. |
10% Owner |
– – • |
2024-02-08 |
4 |
B |
$5.50 |
$9,999,996 |
I/I |
1,818,181 |
12,446,022 |
1.5 |
- |
|
| DALS |
Da32 Life Science Tech Ac... |
10% Owner |
– – • |
2023-07-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,600,000) |
0 |
0 |
- |
|
| CDAK |
Codiak Biosciences, Inc. |
Director |
– • – |
2023-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,750 |
8,750 |
0 |
- |
|
| PRME |
Prime Medicine, Inc. |
10% Owner |
– – • |
2022-10-24 |
4 |
A |
$0.00 |
$0 |
I/I |
11,456,594 |
5,728,297 |
0 |
- |
|
| PRME |
Prime Medicine, Inc. |
10% Owner |
– – • |
2022-10-24 |
4 |
B |
$17.00 |
$13,600,000 |
I/I |
800,000 |
6,128,297 |
1.5 |
% |
|
| CDAK |
Codiak Biosciences, Inc. |
Director |
– • – |
2022-09-13 |
4 |
B |
$0.00 |
$0 |
I/I |
5,000,000 |
7,503,903 |
2.02 |
- |
|
| DALS |
Da32 Life Science Tech Ac... |
10% Owner |
– – • |
2021-07-30 |
4 |
A |
$10.00 |
$6,500,000 |
I/I |
650,000 |
2,250,000 |
0 |
- |
|
| DALS |
Da32 Life Science Tech Ac... |
10% Owner |
– – • |
2021-07-30 |
4 |
B |
$10.00 |
$16,000,000 |
D/D |
1,600,000 |
1,600,000 |
2.45 |
- |
|
| VERV |
Verve Therapeutics, Inc. |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
2,508,809 |
1,254,405 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
10% Owner |
– – • |
2021-02-08 |
4 |
A |
$0.00 |
$0 |
I/I |
43,750,000 |
11,718,750 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
10% Owner |
– – • |
2021-02-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
292,500 |
|
- |
|
| CDAK |
Codiak Biosciences, Inc. |
Director |
– • – |
2020-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
2,204,940 |
2,268,903 |
0 |
- |
|
| CDAK |
Codiak Biosciences, Inc. |
Director |
– • – |
2020-10-16 |
4 |
B |
$15.00 |
$3,525,000 |
I/I |
235,000 |
2,503,903 |
2.1 |
- |
|
| CDAK |
Codiak Biosciences, Inc. |
Director |
– • – |
2020-10-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
63,963 |
|
- |
|
| VBIV |
VBI Vaccines Inc |
Director |
– • – |
2019-09-19 |
4 |
B |
$0.50 |
$5,000,000 |
I/I |
10,000,000 |
13,026,057 |
2.1 |
- |
|
| SNNA |
Sienna Biopharmaceuticals... |
10% Owner |
– – • |
2019-02-22 |
4 |
B |
$2.50 |
$5,414,500 |
I/I |
2,165,800 |
1,865,800 |
1.5 |
- |
|
| QTTB |
Q32 Bio Inc |
Director |
– • – |
2018-04-02 |
4 |
A |
$0.00 |
$0 |
I/I |
6,068,695 |
6,068,695 |
0 |
- |
|
| VBIV |
VBI Vaccines Inc |
Director |
– • • |
2015-08-17 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
3,397,830 |
|
- |
|
| VBIV |
VBI Vaccines Inc |
Director |
– • • |
2015-08-13 |
4 |
A |
$2.10 |
$1,365,000 |
I/I |
650,000 |
4,047,830 |
0 |
- |
|
| BLUE |
Bluebird Bio, Inc. |
Director |
– • – |
2015-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,126 |
18,633 |
0 |
- |
|
| BLUE |
Bluebird Bio, Inc. |
Director |
– • – |
2015-07-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(233,000) |
90,675 |
0 |
- |
|
| BLUE |
Bluebird Bio, Inc. |
Director |
– • – |
2015-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
11,837 |
13,507 |
0 |
- |
|
| BLUE |
Bluebird Bio, Inc. |
Director |
– • – |
2015-06-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(538,076) |
323,675 |
0 |
- |
|
| BLUE |
Bluebird Bio, Inc. |
Director |
– • – |
2015-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
448 |
1,670 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
